Compare Johnson & Johnson (JNJ) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs S&P Global Inc — how do they compare? Johnson & Johnson trades at $260.72 (market cap $618.09B), while S&P Global Inc trades at $407.75 (market cap $118.72B). The key difference: Johnson & Johnson is far larger — about 5.2× S&P Global Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and S&P Global Inc for 123 Days on average.
| JNJ | SPGI | |
|---|---|---|
Market Cap | $618.09B | $118.72B |
Volume | 6,050,983 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $278.43 | $517.92 |
52-Week Low | $186.00 | $370.42 |
Typical Hold Time | 129 Days | 123 Days |
Enterprise Value | $646.37B | $130.21B |
Dividend Yield | 2.09% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
S&P Global (SPGI) trades at $406.06, up 2.75% today, with strong analyst support (85.7% buy ratings) and a consensus price target of $509.50. The stock shows robust fundamentals, including 30.54% net income margin and consistent revenue growth, though technical indicators signal near-term bearish pressure. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives, positioning the company for future revenue streams.
Outlook remains positive due to high profitability, strategic acquisitions, and dominant market position, but risks include competitive pressures and macroeconomic sensitivity. The stock offers upside based on analyst targets, supported by stable cash flows and dividend payments, making it a compelling hold for long-term investors despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
